Abstract:Acinetobacter species lead to nosocomial infections in immunocompromised patients hospitalized in intensive care units or services. Acinetobacter baumannii is a bacterium that is difficult to treat because it is intrinsically resistant to many antibiotics and can develop resistance afterwards. This situation limits the use of existing antibiotics and directs the clinician to new agents, different treatment options and the use of various antibiotic combinations. The aim of this study was to determine the sensitivities of doripenem (DOR), tigecycline (TGC), minocycline (MIN), amikacin (AK) and a newly developed agent ceftolozane-tazobactam (CT) in multidrug resistant A.baumannii strains which were isolated from inpatients in intensive care units and to investigate the in vitro interactions of CT/DOR, CT/TGC, CT/MIN and CT/AK combinations by using antibiotic gradient test method. Thirty-five A.baumannii strains isolated from various clinical specimens (blood, urine, sputum, tracheal aspirate, wound, abscess and catheter) between January 2017 and July 2017 were included in the study. Strains isolated from inpatients in intensive care units and resistant to at least three antibiotic classes were selected. The identification of A.baumannii isolates and the determination of routine antibiotic susceptibility profile were performed according to EUCAST 2017 criteria by the use of BD Phoenix 100 (Becton Dickinson, USA) automated system. Minimum inhibitor concentration values of CT, DOR, TGC, MIN, AK and combinations of CT with four other antibiotics (CT/DOR, CT/TGC, CT/MIN and CT/AK) were determined by antibiotic gradient test method. Fractional inhibitor concentration index (FICI) was used to determine the interactions of the combinations in vitro. According to the data obtained; the FICI was evaluated as synergy if FICI ≤ 0.5, additive if 0.5 > FICI ≤ 1, indifferent (unidentified interaction) if 1 <FICI <2 and antagonist interaction if FICI ≥ 2. According to FICI results of the antibiotic combinations, the highest synergistic interaction was observed between CT/TGC as 11.4%. No synergistic interaction was observed between CT/DOR antibiotics. The highest additive interaction rates were between CT/AK (60%) and CT/MIN (45.7%), while no additive interaction between CT/DOR was observed. Antagonist interaction was observed in CT/DOR (71.4%) combination only. In conclusion, in our study it was observed that CT, a novel beta-lactam/ beta-lactamase inhibitor, did not sufficiently affect A.baumannii isolates, but was able to induce synergistic interaction in combination with TGC, AK and MIN. CT should be carefully monitored in clinical use because of the antagonist interaction detected with DOR.

In vitro antibacterial activity of cefoperazone combined with tazobactam against clinical isolates producing β-lactamases

In Vitro Antibacterial Activity of Cefoperazone/Tazobactam and Its Impact Factors

Antimicrobial Agents Including Cefmetazole Against Extended-spectrum Beta-lactamases-producing Enterobacteriaceae: an in Vitro Susceptibility Investigation

In vitro and in vivo synergistic antibacterial activity of cefotaxime/sulbactam

In Vitro Antibacterial Activities of Different Ratios from Matching Cefuroxime/tazobactam Against Clinical Isolates

Study on enzyme stability of cefotaxime/tazobactam to β-lactamases

Efficacy of synergistic antibiotic combinations against KPC-2 carbapenemase producing Klebsiella pneumoniae strains

In vitro antibacterial activities of different ratios from matching cefotaxime/tazobactam

In vitro Effect of the Combination of Aztreonam and Amoxicillin/Clavulanic Acid Against Carbapenem-Resistant Gram-Negative Organisms Producing Metallo--Lactamase

Comparison of antimicrobial activity in vitro of 7 β-lactams against 280 isolates from patients with nosocomial infections

Antibacterial activity study of several β-lactam/β-lactamase inhibitor combinations in vitro

Treatment effects of the combination of cefuroxime and tazobactam against mouse septicemia infected by β-lactamases producing strains

Stability of cefuroxime/tazobactam to β-lactamases and ability of tazobactam in preventing hydrolysis

In vitro antibacterial activity of 13 antibiotics against bacteria producing AmpC β-lactamases or AmpC β-lactamases plus ESBLs

In vitro activity of different ratios from matching cefotaxime/culbactam

Antibacterial Activity of Cefoperazone-Sulbactam Against Nonfermentative Gram Negative Rods

In vitro effect of cefoperazone-sulbactam (2:1, 1: 1) combined with minocycline on imipenem-resistant Acinetobacter baumannii clinical isolates

[In-vitro Activity of Ceftolozane-Tazobactam in Combination with Various Antibiotics Against Multidrug-resistant Acinetobacter baumannii Isolated from Intensive Care Patients]

Study of in vitro antibacterial activity by combined sensitivity tests for multiple-drug resistant Pseudomonas aeruginosa

In vitro Synergistic and Bactericidal Effects of Aztreonam in Combination with Ceftazidime/ Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam Against Dual-Carbapenemase-Producing Enterobacterales

In vitro activity of tigecycline in combination with cefoperazone-sulbactam against multidrug-resistant Acinetobacter baumannii